Shionogi’s Sakigake-Designated Flu Med Up for MHLW Panel Review on Feb. 2, Early Listing Possible?

January 23, 2018
Shionogi’s influenza type A/B treatment S-033188 (baloxavir marboxil) will come up for approval review by a key Japanese health ministry panel on February 2, becoming the first drug designated under the sakigake fast-track pathway to reach this stage. If the...read more